share_log

Blueprint Medicines Reports European Medicines Agency Validation Of Co.'s Type 2 Variation Marketing Authorization Application For AYVAKYT For Treatment Of Advanced Systemic Mastocytosis

Blueprint Medicines Reports European Medicines Agency Validation Of Co.'s Type 2 Variation Marketing Authorization Application For AYVAKYT For Treatment Of Advanced Systemic Mastocytosis

Blueprint Medicines报告欧洲药品管理局对AYVAKYT公司治疗晚期系统性肥大细胞增多症的2型变异营销授权申请的验证
Benzinga Real-time News ·  2021/03/03 21:04

Blueprint Medicines Reports European Medicines Agency Validation Of Co.'s Type 2 Variation Marketing Authorization Application For AYVAKYT For Treatment Of Advanced Systemic Mastocytosis

Blueprint Medicines报告欧洲药品管理局对AYVAKYT公司治疗晚期系统性肥大细胞增多症的2型变异营销授权申请的验证

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发